无诱因静脉血栓栓塞症患者抗凝治疗后癌症风险:一项观察性队列研究
本研究随访1188例首次无诱因静脉血栓栓塞症且已停用抗凝治疗的患者,中位随访98个月,62例(5.2%)发生癌症。1年、5年、15年累积癌症发生率分别为0.7%、3.1%、9%,与匹配的一般人群(0.6%、3.4%、12.2%)无显著差异。年龄增长和抗凝持续时间较短与癌症风险增加相关,而静脉血栓栓塞症复发不能预测未来癌症诊断。
要点
- 停用抗凝治疗的无诱因静脉血栓栓塞症患者,长期癌症风险不高于一般人群。
- 年龄增长(每增加10年HR 1.5)和抗凝持续时间缩短(每减少1个月HR 1.3)与癌症风险增加相关。
- 静脉血栓栓塞症复发不能预测未来癌症诊断(HR 1.17,95%CI 0.66-2.07)。
核心结论
- 已完成抗凝治疗的无症状无诱因静脉血栓栓塞症患者,其癌症风险不高于一般人群。
- 抗凝持续时间与癌症发生率之间的反向关联需进一步研究。
研究设计与样本
- 观察性队列研究,随访首次无诱因静脉血栓栓塞症且停用抗凝治疗的患者,排除接受长期抗血栓治疗或存在重大血栓形成倾向者。
- 共纳入1188例患者,中位随访98个月。
主要发现
- 1188例患者中62例(5.2%)在中位随访98个月期间发生癌症。
- 1年、5年和15年累积癌症发生率分别为0.7%(95%CI 0.2-1.2%)、3.1%(95%CI 2.0-4.1%)和9%(95%CI 6.5-11.5)。
- 匹配的一般人群1年、5年和15年癌症发生率分别为0.6%、3.4%和12.2%,与本队列无显著差异。
- 相应的标准化发病比分别为1.1(95%CI 0.5-2.5)、1.0(95%CI 0.6-1.4)和0.9(95%CI 0.7-1.2),未提示本队列与一般人群癌症发生率存在差异。
- 年龄增长(每增加10年HR 1.5,95%CI 1.2-2.0)和抗凝持续时间缩短(每减少1个月HR 1.3,95%CI 1.1-1.6)与癌症风险增加相关,而静脉血栓栓塞症复发与癌症风险无关(HR 1.17,95%CI 0.66-2.07)。
局限性
- 抗凝持续时间与癌症发生率之间的反向关联需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials Data on long-term cancer risk are controversial in patients with venous thromboembolism (VTE). We assessed long-term rates and risk factors of cancer in patients with VTE. Cancer risk after anticoagulation is not higher in VTE patients than in the general population. VTE recurrence is not predictive of a future cancer diagnosis. SUMMARY: Background Patients with venous thromboembolism (VTE) are at risk of having a subsequent cancer diagnosis. The risk is highest during the first 6 months. Reports on cancer rates thereafter are controversial. We aimed to assess long-term rates and risk factors of cancer in patients with VTE. Methods and Results We followed patients with a first unprovoked VTE after discontinuation of anticoagulation, and excluded those receiving long-term antithrombotic therapy or with major thrombophilia. The study endpoint was the occurrence of cancer. Sixty-two (5.2%) of 1188 patients developed cancer during a median follow-up of 98 months. The cumulative incidence rates of cancer were 0.7% (95% confidence interval [CI] 0.2-1.2%), 3.1% (95% CI 2.0-4.1%) and 9% (95% CI 6.5-11.5) after 1, 5 and 15 years; these were not significantly different from those in the matched general population (0.6%, 3.4%, and 12.2%, respectively). The corresponding standardized incidence ratios (ratio of the observed cancer cases and the number of cases based on national cancer incidence rates) of 1.1 (95% CI 0.5-2.5), 1.0 (95% CI 0.6-1.4) and 0.9 (95% CI 0.7-1.2) did not indicate a difference in cancer incidence between our cohort and the general population. Advancing age (hazard ratio [HR] per decade 1.5, 95% CI 1.2-2.0) and shorter duration of anticoagulation (HR per 1-month decrease 1.3, 95% CI 1.1-1.6) were associated with an increased cancer risk, whereas VTE recurrence was not (HR 1.17, 95% CI 0.66-2.07). Conclusions Asymptomatic patients with unprovoked VTE who have completed anticoagulation therapy do not have a higher cancer risk. The inverse association between the duration of anticoagulation and the incidence of cancer warrants further investigation.
引用
- Eischer L, Kammer M, Traby L, et al. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study. J Thromb Haemost. 2017. PMID: 28407356. doi:10.1111/jth.13702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。